We advise you to exercise Sinovac Biotech fundamental analysis to find out if markets are presently mispricing the corporation. In other words this interface allows you to confirm available indicators of Sinovac Biotech as well as the relationship between them. We found thirty-five available drivers for Sinovac Biotech Ltd which can be compared to its competition. To make sure the equity is not overpriced, please validate all Sinovac Biotech fundamentals including its Debt to Equity, Market Capitalization and the relationship between Net Income and Short Ratio . As Sinovac Biotech appears to be a penny stock we also recommend to double-check its Number of Shares Shorted numbers.
Sinovac Biotech Company Summary
Sinovac Biotech competes with Vertex Pharmaceuticals, Dr Reddys, Zoetis, Perrigo Company, and Regeneron Pharmaceuticals. Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the Peoples Republic of China. Sinovac Biotech Ltd. was founded in 1999 and is based in Beijing, the Peoples Republic of China. Sinovac Biotech operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 735 people.
Sinovac Biotech Debt to Equity vs Price to Earning
Sinovac Biotech Ltd is rated third in debt to equity category among related companies. It is currently regarded as top stock in price to earning category among related companies reporting about 4.55 of Price to Earning per Debt to Equity.
|Debt to Equity ( % )|
|Price to Earning ( times )|
Sinovac Biotech Market Fundamentals